GrandOmics (希望组)

Beijing, China

As the world’s largest next-generation sequencing application company, the world’s largest Oxford Nanopore sequencing center and the first third-generation sequencing precision medical company, Grandomics provides sophisticated genomic analysis solutions that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. At present, Grandomics has fully launched the third-generation sequencing services in the field of genetic diseases, tumors and human microbiome , including whole genome sequencing, full-length transcriptome sequencing, whole genome methylation sequencing and so on, which offer the most comprehensive view of genomes, transcriptomes, and epigenomes — including the full spectrum of genetic variations. We believe that our services will lead to advances that will create long-lasting benefits for clinical medicine and human health.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out GrandOmics (希望组) on @MedStartr Today #MicrobiomeHealth #Cancer #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/DEjcEeuogBM

Get Involved in GrandOmics (希望组)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2014
Website: www.grandomics.com/

Disease Areas

Microbiome Health

Technologies

Next-Generation SequencingGenomic SequencingWhole Genome SequencingWhole Transcriptome Sequencing (WTS)

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of GrandOmics (希望组)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.